Currently, there is no screening algorithm for asymptomatic women [7] but some strategies can help to discriminate malignant from benign lesions such as carbohydrate antigen 125 (CA125) [8], human epididymis protein 4 (HE4) [9], ultrasonography, risk of malignancy algorithm (ROMA), risk of ovarian cancer algorithm (ROCA), and risk of malignancy index (RMI) [10]. This evidence concerns the gene WFDC2 and ovarian carcinoma.